Introduction {#jcmm13323-sec-0001}
============

Interleukin (IL)‐18 is a product of the inflammasome, which is involved in host defence against viral and bacterial stimuli by modulating the immune response [1](#jcmm13323-bib-0001){ref-type="ref"}. Recently, however, evidence has accumulated that IL‐18 expression is increased in many presentations of allergic disease [2](#jcmm13323-bib-0002){ref-type="ref"}. In particular, it is required for differentiation of regulatory T cells and protection against allergic asthma [3](#jcmm13323-bib-0003){ref-type="ref"}. It was observed that IL‐18 and IL‐18 receptor (IL‐18R) were strongly expressed in the lungs of fatal asthma [4](#jcmm13323-bib-0004){ref-type="ref"}, serum IL‐18 levels were significantly high in asthmatic children [5](#jcmm13323-bib-0005){ref-type="ref"} and IL‐18 variants were significantly associated with asthma severity [6](#jcmm13323-bib-0006){ref-type="ref"}, implicating that IL‐18 likely contributes to the development of asthma.

IL‐18R is part of the IL‐1R/TLR superfamily signalling *via* a MyD88‐dependent pathway. A wide range of cells including Th1 cells [7](#jcmm13323-bib-0007){ref-type="ref"}, natural killer cells, natural killer T cells, mast cells and basophils expresses the IL‐18R [8](#jcmm13323-bib-0008){ref-type="ref"}.

IL‐18 (BP) is an endogenous antagonist with high neutralizing capacity that inhibits the action of IL‐18 by preventing interaction with its cell surface receptors [9](#jcmm13323-bib-0009){ref-type="ref"}. At a molar excess of two, IL‐18BP neutralizes IL‐18 to \>95% [10](#jcmm13323-bib-0010){ref-type="ref"}. An imbalance between IL‐18 and IL‐18BP expression may account for increased IL‐18 activity in asthma. However, little is known about expression of IL‐18BP and IL‐18R in monocytes, neutrophils and B cells in asthma.

It has been reported that *Alternaria* extract induced rapid release of IL‐18 from cultured normal human bronchial epithelial cells and directly initiated Th2 differentiation [11](#jcmm13323-bib-0011){ref-type="ref"}, and that IL‐18 can induce release of IFN‐γ, IL‐13 and eotaxin in the lungs of ovalbumin‐sensitized and challenged transgenic mice along with an airway hyper‐responsiveness [12](#jcmm13323-bib-0012){ref-type="ref"}, suggesting that allergens may cause allergic airway disorders through IL‐18‐related mechanisms. However, little is known about influence of allergens on expression of IL‐18, IL‐18BP and IL‐18R in asthma.

The findings that increased release of IL‐18 by airway macrophages is associated with both the acute and chronic forms of hypersensitivity pneumonitis [13](#jcmm13323-bib-0013){ref-type="ref"}, that IL‐18 is located in neutrophils [14](#jcmm13323-bib-0014){ref-type="ref"} and facilitates neutrophil transmigration [15](#jcmm13323-bib-0015){ref-type="ref"}, that IL‐18 down‐regulates B‐cell migration [16](#jcmm13323-bib-0016){ref-type="ref"}, and that virus antigen EBNA2 induces expression of IL‐18R in B cells [17](#jcmm13323-bib-0017){ref-type="ref"} implicate that macrophage, neutrophils and B cells may participate in the development of airway inflammatory disorders including asthma *via* a IL‐18‐related mechanism. Therefore, the aim of this study is to investigate the expression of IL‐18, IL‐18BP and IL‐18R in inflammatory cells of atopic asthma, and influence of allergens on their expression.

Materials and methods {#jcmm13323-sec-0002}
=====================

Reagents {#jcmm13323-sec-0003}
--------

The following reagents were purchased from Biolegend (San Diego, CA, USA): red blood cell lysis buffer, PE/Cy7‐conjugated mouse anti‐human CD14 antibody, PerCP‐conjugated mouse anti‐human CD16 antibody, APC/Cy7‐conjugated mouse anti‐human CD19 antibody, APC/Cy7‐conjugated rat antimouse Ly‐6G/Ly‐6C antibody, Brilliant Violet (BV) 421‐conjugated rat antimouse CD11b antibody, APC/Cy7‐conjugated Armenian Hamster antimouse CD11c antibody, PE/Cy7‐conjugated rat antimouse F4/80 antibody, BV510‐conjugated donkey anti‐rabbit IgG polyclonal antibody, Zombie Aqua™ Fixable Viability Kit, Zombie Green™ Fixable Viability Kit, human Fc receptor blocking solution, antimouse CD16/32 antibody and brefeldin A. FITC‐conjugated rabbit antimouse IL‐18BP polyclonal antibody was from Cloud clone (Houston, TX, USA). Recombinant mouse IL‐18 protein, APC‐conjugated mouse anti‐human IL‐18Rα antibody, PE‐conjugated mouse anti‐human IL‐18 antibody, APC‐conjugated rat antimouse IL‐18R antibody and their isotype antibodies: mouse IgG1 APC‐conjugated antibody, mouse IgG1 PE‐conjugated antibody and rat IgG1 APC‐conjugated antibody were supplied by R&D Systems (Minneapolis, MN, USA). Rabbit anti‐human IL‐18BP antibody and its isotype antibody rabbit IgG were obtained from Abcam (Cambridge, UK). Ovalbumin (OVA, Grade V), trypan blue dye, collagenase, hyaluronidase and DNase were purchased from Sigma‐Aldrich (St Louis, MO, USA). Cytofix/Cytoperm™ Fixation/Permeabilization Kit was bought from BD Biosciences Pharmigen (Beldford, MA, USA). Human IL‐18BP and human IL‐18 ELISA kit were bought from ImmunoWay Biotechnology Company (Newark, DE, USA) and ExCell Bio (Shanghai, China), respectively. Foetal bovine serum (FBS, Hyclone) and RPMI 1640 were purchased from Gibco BRL (Grand Island, NY, USA). *Artemisia sieversiana* wild allergen extract (ASWE), *Dermatophagoide* allergen extract (DAE) or *Platanus* pollen allergen extract (PPAE) were offered by Macro Union Pharmaceutical Co. Ltd (Beijing, China). Allergens for skin prick tests were supplied by ALK‐Abelló, Inc. (Denmark). Most of the general‐purpose chemicals such as salts and buffer components were of analytical grade.

Volunteers and animals {#jcmm13323-sec-0004}
----------------------

A total of 31 patients with asthma and 14 healthy control (HC) volunteer were recruited in the study. Their general characteristics were summarized in Table [1](#jcmm13323-tbl-0001){ref-type="table-wrap"}. The diagnosing criteria of asthma were conformed to the Global Initiative for Asthma [18](#jcmm13323-bib-0018){ref-type="ref"}. All mild asthmatic patients were asked to stop anti‐allergy medication for at least 2 weeks prior to attending the study (those could not stop anti‐allergy drugs were excluded). The recruited patients did not have any airway infection more than one month.

###### 

Characteristics of adult volunteers

  Population         Case   Age (year)    Female/male   History (year)   Onset age (year)
  ------------------ ------ ------------- ------------- ---------------- ------------------
  HC                 14     25 (22--28)   9/5           0                0
  Asthma             31     35 (18--65)   20/11         3.5 (0--30)      36 (18--57)
  Cockroach (+)      2      24 (20--28)   1/1           2 (1--3)         22 (19--25)
  Mite (+)           16     40 (18--65)   10/6          10 (0.5--30)     33 (18--35)
  Grass pollen (+)   7      32 (18--52)   5/2           3.5 (1--6)       26 (16--48)
  Tree pollen (+)    6      28 (24--60)   4/2           2.5 (0--4.5)     39 (23--57)

Median values (range) are shown. Specific allergens were examined by skin prick test. HC = healthy control.
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The informed consent from each volunteer according to the declaration of Helsinki and agreement with the Ethical Committee of the Second Affiliated Hospital of Shenyang Medical College, or with the General Hospital of Shenyang Military Region of PLA, or with the First Affiliated Hospital of Jinzhou Medical University was obtained (Trial registry: Chinese clinical trial; registration number: ChiCTR‐BOC‐16010279).

Immediately after admission (acute exacerbation stage), the blood from each patient with asthma was collected. Blood from HCs was collected in the outpatient clinic. From each individual, 10 ml of peripheral blood was taken into an EDTA containing tube before centrifugation at 450 × *g* for 10 min. The cells were used for flow cytometric analysis, and plasma was collected and frozen at −80°C until use.

Female BALB/c mice (4--6 w, 18--22 g) were obtained from Vital River Laboratory Animal Technology Co. Ltd (Beijing, China), Certificate No 11400700118760. The animals were bred and reared under strict ethical conditions according to international recommendations. They were housed in the Animal Experimental Center of the First Affiliated Hospital of Jinzhou Medical University in a specific pathogen‐free environment with free access to standard rodent chow and water, at a constant temperature 23--28°C and relative humidity of 60--75%. The animal experiment procedures were approved by the Animal Care Committee at Jinzhou Medical University.

Flow cytometry analysis of IL‐18, IL‐18BP and IL‐18R in human peripheral blood monocytes, neutrophils and B cells {#jcmm13323-sec-0005}
-----------------------------------------------------------------------------------------------------------------

To detect expression of IL‐18, IL‐18BP and IL‐18R in human blood monocytes, neutrophils and B cells, blood cells were stimulated with or without ASWE, DAE or PPAE (all at a concentration of 1.0 μg/ml) for 1 hr at 37°C, respectively, and 2 μg/ml brefeldin A was also added into the tube. Cells were then incubated with human Fc receptor blocking solution and a live/dead cell dye (Zombie Green™ Fixable Viability Kit [19](#jcmm13323-bib-0019){ref-type="ref"} for 15 min., and each labelled monoclonal antibody including PE/Cy7‐conjugated anti‐human CD14, PerCP‐conjugated anti‐human CD16, APC/Cy7‐conjugated anti‐human CD19 and APC‐conjugated anti‐human IL‐18Rα was added into the tube. After red blood cells being lysed, resuspended leucocytes were fixed and permeabilized using Cytofix/Cytoperm™ Fixation/Permeabilization Kit according to the manufacturer\'s instructions. This was followed by adding PE‐conjugated anti‐human IL‐18 and anti‐human IL‐18BP primary antibodies into the tube and incubated at 4°C for 30 min. BV510‐conjugated donkey anti‐rabbit polyclonal antibody was added into each tube for 30 min. at room temperature. Finally, cells were resuspended in fluorescence‐activated cell sorting (FACS)‐Flow solution and analysed with FACS Verse flow cytometer (BD Biosciences, San Jose, CA). A total of 10,000 events in live cell gate were analysed for each sample. Data were analysed with FlowJo software version 7.0 (Treestar, Ashland, OR, USA). Dead cells and doublets were excluded from analysis by live/dead cell dyes.

Mouse sensitization and challenge {#jcmm13323-sec-0006}
---------------------------------

Mice were sensitized on days 0, 7, 14 and 21 with an subcutaneous multi‐point injection of 50 μg OVA and 1.5 mg of Al (OH)~3~ suspended in NS to a total volume of 0.5 ml. Non‐sensitized control animals received only the equal volume (0.5 ml) of NS on the same days. On day 25, sensitized mice were challenged with intratracheal injection of 0.1 ml of 5% OVA solution with or without 10 ng/ml of IL‐18 for 3 hrs. After being killed, blood from mice was collected. The cells were used for flow cytometric analysis, and plasma was collected and frozen at −80°C until use. Lung tissues were excised and digested into dispersed cells as described previously [20](#jcmm13323-bib-0020){ref-type="ref"}.

Flow cytometry analysis of IL‐18BP and IL‐18R in mouse blood monocytes and neutrophils, and lung macrophages {#jcmm13323-sec-0007}
------------------------------------------------------------------------------------------------------------

To detect IL‐18BP and IL‐18R expression on monocytes and neutrophils, cells were incubated with antimouse CD16/32, and a live/dead cell dye (Zombie Aqua™ Fixable Viability Kit) [21](#jcmm13323-bib-0021){ref-type="ref"} for 15 min. Each labelled monoclonal antibody including APC/Cy7‐conjugated antimouse Ly‐6G/Ly‐6C [22](#jcmm13323-bib-0022){ref-type="ref"}, BV421‐conjugated antimouse CD11b and APC‐conjugated antimouse IL‐18R was added into tubes for 15 min. Red blood cells were lysed, and leucocytes were fixed and permeabilized using Cytofix/Cytoperm™ Fixation/Permeabilization Kit according to the manufacturer\'s instructions. FITC‐conjugated antimouse IL‐18BP was then added into each tube. Finally, cells were processed as for human blood samples and analysed by flow cytometer.

To detect IL‐18BP and IL‐18R expression in macrophages, dispersed cells were incubated with antimouse CD16/32 and a live/dead cell dye (Zombie Aqua™ Fixable Viability Kit) [21](#jcmm13323-bib-0021){ref-type="ref"} for 15 min. APC/Cy7‐conjugated antimouse CD11c, PE/Cy7‐conjugated antimouse F4/80 and APC‐conjugated antimouse IL‐18R antibodies were then added into the tube for 15 min. Cells were finally processed and analysed as above.

Determination of levels of IL‐18 and IL‐18BP {#jcmm13323-sec-0008}
--------------------------------------------

Levels of IL‐18 and IL‐18BP in human plasma were measured using ELISA kits according to the manufacturer\'s instruction.

Statistics {#jcmm13323-sec-0009}
----------

Statistical analyses were performed using SPSS software (Version 17.0; IBM Corporation, Armonk, NY, USA). Data for expression of IL‐18, IL‐18BP and IL‐18R in leucocytes are displayed as a boxplot, which indicates the median, interquartile range, the largest and smallest values for the number of experiments indicated. Plasma levels of IL‐18 and IL‐18BP are presented as scatter plot. Kruskal--Wallis analysis indicated significant differences between groups, and for the pre‐planned comparisons of interest, the paired Mann--Whitney *U*‐test was employed. For all analyses, *P* \< 0.05 was taken as significant.

Results {#jcmm13323-sec-0010}
=======

Elevated levels of IL‐18 and IL‐18BP in asthmatic plasma {#jcmm13323-sec-0011}
--------------------------------------------------------

Serum IL‐18 level was found significantly higher in children who had asthma [5](#jcmm13323-bib-0005){ref-type="ref"}, but the plasma/serum level of IL‐18BP in asthma, and correlation between IL‐18 and IL‐18BP has not been investigated. Using ELISA kits, we observed that levels of IL‐18 were 270.7 and 169.0 pg/ml (Fig. [1](#jcmm13323-fig-0001){ref-type="fig"}A), and levels of IL‐18BP were 3460 and 1910 pg/ml (Fig. [1](#jcmm13323-fig-0001){ref-type="fig"}B) in the plasma of patients with asthma and HC volunteers, respectively. The ratio between plasma concentrations of IL‐18 and IL‐18BP was 1:12.8 in asthmatic patients. It was observed that IL‐18 and IL‐18BP were correlated well with each other in the plasma of patients with asthma and HC volunteers (Fig. [1](#jcmm13323-fig-0001){ref-type="fig"}C).

![Scatter plots of levels of IL‐18 (**A**) and IL‐18BP (**B**) in plasma of asthmatic and healthy control (HC) volunteers. Each symbol represents the value from 1 volunteer. The median value is indicated with a horizontal line. *P* \< 0.05 was taken as statistically significant. (**C**) The spearman\'s rho/correlation coefficient between the plasma level of IL‐18 and IL‐18BP. \* *P* \< 0.05.](JCMM-22-354-g001){#jcmm13323-fig-0001}

Enhanced CD14^+^ monocytes and IL‐18R^+^ monocytes in peripheral blood of patients with atopic asthma {#jcmm13323-sec-0012}
-----------------------------------------------------------------------------------------------------

Little is known about the sources of increased plasma level of IL‐18 and expression level of IL‐18R on inflammatory cells in asthma. We therefore examined expression levels of IL‐18, IL‐18BP and IL‐18R in monocytes of asthmatic blood. The results showed that percentage of CD14^+^ monocytes in asthmatic blood was much greater than that in HC blood. The allergens tested had little effect on number of monocytes (Fig. [2](#jcmm13323-fig-0002){ref-type="fig"}A and B).

![Expression of IL‐18, IL‐18BP and IL‐18 receptor (R) in peripheral blood CD14^+^ monocytes of asthma patients and healthy control (HC) volunteers in the presence or absence of *Artemisia*,*Dermatophagoide* and *Platanus* allergens. (**A**) represents a gating strategy of CD14^+^ monocytes in leucocytes. (**B**) shows proportion of CD14^+^ monocytes in human peripheral blood leucocytes. (**C**) is a gating strategy of expression of IL‐18, IL‐18BP and IL‐18R in CD14^+^ monocytes. (**D**--**F**) demonstrates percentages of IL‐18, IL‐18BP and IL‐18R expressing monocytes in leucocytes, respectively. (**G**) shows representative flow cytometric figures of MFI of IL‐18^+^ (i), IL‐18BP^+^ (ii) and IL‐18R^+^ (iii) monocyte. (**H**--**J**) shows mean fluorescent intensity (MFI) of IL‐18, IL‐18BP and IL‐18R expression in monocyte, respectively. Data are displayed as a boxplot for asthma patients (*n* = 31), and HC volunteers (*n* = 14), which indicates the median, interquartile range, the largest and smallest values for the number of volunteers indicated. *P* \< 0.05 was taken as statistically significant. FMO = fluorescence minus one. ^‡^ *P* \< 0.05 in comparison with HC group.](JCMM-22-354-g002){#jcmm13323-fig-0002}

Approximately 8.2% and 7.3% of monocytes in HC and asthmatic blood expressed IL‐18, respectively. ASWE appeared to enhance IL‐18 expression in monocytes (Fig. [2](#jcmm13323-fig-0002){ref-type="fig"}C and D). More than 95% CD14^+^ monocytes in asthmatic or HC blood expressed IL‐18BP regardless of presence of allergens or not (Fig. [2](#jcmm13323-fig-0002){ref-type="fig"}C and E), which indicates 13‐fold more monocytes express IL‐18BP than IL‐18 in asthmatic blood. We also observed that percentage of IL‐18R^+^ monocytes was enhanced in asthmatic blood compared with that in HC blood. The allergens tested had little effect on IL‐18R expression on monocytes (Fig. [2](#jcmm13323-fig-0002){ref-type="fig"}C and F).

In terms of MFI (mean fluorescence intensity), ASWE and PPAE enhanced MFI of IL‐18 in asthmatic monocytes (Fig. [2](#jcmm13323-fig-0002){ref-type="fig"}Gi and H). On the other hand, asthmatic monocytes seemed to have less MFI of IL‐18BP than that in HC monocytes (Fig. [2](#jcmm13323-fig-0002){ref-type="fig"}Gii and I). The allergens tested had little influence on MFI of IL‐18R expressed in monocytes (Fig. [2](#jcmm13323-fig-0002){ref-type="fig"}Giii and J).

Enhanced expression of IL‐18 and IL‐18R in asthmatic neutrophils {#jcmm13323-sec-0013}
----------------------------------------------------------------

It has been reported that human neutrophil can release IL‐18 [14](#jcmm13323-bib-0014){ref-type="ref"}, which can be a source of enhanced plasma IL‐18 of asthma patients. To further understand the involvement of IL‐18 in asthma, we examined expression of IL‐18, IL‐18BP and IL‐18R in peripheral blood neutrophils. The results showed that CD16^+^ neutrophils occupied approximately 73.5% and 70.6% leucocytes in HC and asthmatic blood (Fig. [3](#jcmm13323-fig-0003){ref-type="fig"}A and B). However, only 2.6% and 4.0% neutrophils expressed IL‐18 (Fig. [3](#jcmm13323-fig-0003){ref-type="fig"}C and D), and 0.1% and 1.7% neutrophils expressed IL‐18R in HC and asthmatic blood (Fig. [3](#jcmm13323-fig-0003){ref-type="fig"}C and F). On the other hand, more than 70% neutrophils in HC and asthmatic blood expressed IL‐18BP (Fig. [3](#jcmm13323-fig-0003){ref-type="fig"}C and E). We then worked out that approximately 17.5‐fold more neutrophils express IL‐18BP than IL‐18 in asthmatic blood. Moreover, ASWE and DAE increased proportions of IL‐18BP^+^ neutrophils when they were added to asthmatic blood (Fig. [3](#jcmm13323-fig-0003){ref-type="fig"}E). Asthmatic neutrophils seemed to have less MFI of IL‐18R than that in HC neutrophils (Fig. [3](#jcmm13323-fig-0003){ref-type="fig"}Giii and J). The allergens had little effect on MFI of IL‐18, IL‐18BP and IL‐18R in neutrophils (Fig. [3](#jcmm13323-fig-0003){ref-type="fig"}G--J).

![Expression of IL‐18, IL‐18BP and IL‐18 receptor (R) in peripheral blood CD16^+^ neutrophils of asthma patients and healthy control (HC) volunteers in the presence or absence of *Artemisia*,*Dermatophagoide* and *Platanus* allergens. (**A**) represents a gating strategy of CD16^+^ neutrophils in leucocytes. (**B**) shows proportion of CD16^+^ neutrophils in human peripheral blood leucocytes. (**C**) is a gating strategy of expression of IL‐18, IL‐18BP and IL‐18R in CD16^+^ neutrophils. (**D**--**F**) demonstrates percentages of IL‐18, IL‐18BP and IL‐18R expressing neutrophils in leucocytes, respectively. (**G**) shows representative flow cytometric figures of MFI of IL‐18^+^ (i), IL‐18BP^+^ (ii) and IL‐18R^+^ (iii) neutrophil. (**H**--**J**) show mean fluorescent intensity (MFI) of IL‐18, IL‐18BP and IL‐18R expression in neutrophil, respectively. Data are displayed as a boxplot for asthma patients (*n* = 31), and HC volunteers (*n* = 14), which indicates the median, interquartile range, the largest and smallest values for the number of volunteers indicated. *P* \< 0.05 was taken as statistically significant. \**P* \< 0.05 compared with medium control in asthma group. ^‡^ *P* \< 0.05 compared with medium control in HC group. FMO = fluorescence minus one.](JCMM-22-354-g003){#jcmm13323-fig-0003}

Enhanced expression of IL‐18 and IL‐18R in asthmatic B cells {#jcmm13323-sec-0014}
------------------------------------------------------------

Little is known about expression of IL‐18, IL‐18BP and IL‐18R in peripheral blood B cells, and we therefore examined expression of them in B cells of asthma patients. The results showed that proportion of CD19^+^ B cells increased in asthmatic blood compared with that in HC blood (Fig. [4](#jcmm13323-fig-0004){ref-type="fig"}A and B). Proportions of IL‐18^+^ (Fig. [4](#jcmm13323-fig-0004){ref-type="fig"}C and D) and IL‐18R^+^ (Fig. [4](#jcmm13323-fig-0004){ref-type="fig"}C and F) B cells were also increased in asthmatic blood in comparison with those in HC blood. Approximately 69.3% and 69.1% B cells in HC and asthmatic blood expressed IL‐18BP (Fig. [4](#jcmm13323-fig-0004){ref-type="fig"}C and E). It was observed that 4.1‐fold more B cells express IL‐18BP than IL‐18 in asthmatic blood. The allergens tested in this study did not alter proportions of IL‐18^+^, IL‐18BP^+^ and IL‐18R^+^ B cells in HC and asthmatic blood (Fig. [4](#jcmm13323-fig-0004){ref-type="fig"}D--F). However, DAE seemed to induce elevated MFI of IL‐18 (Fig. [4](#jcmm13323-fig-0004){ref-type="fig"}Gi and H) and IL‐18BP (Fig. [4](#jcmm13323-fig-0004){ref-type="fig"}Gii and I) in B cells of asthma patients.

![Expression of IL‐18, IL‐18BP and IL‐18 receptor (R) in peripheral blood CD19^+^ B cells of asthma patients and healthy control (HC) volunteers in the presence or absence of *Artemisia*,*Dermatophagoide* and *Platanus* allergens. (**A**) represents a gating strategy of CD19^+^ B cells in leucocytes. (**B**) shows proportion of CD19^+^ B cells in human peripheral blood leucocytes. (**C**) is a gating strategy of expression of IL‐18, IL‐18BP and IL‐18R in CD19^+^ B cells. (**D**--**F**) demonstrates percentages of IL‐18, IL‐18BP and IL‐18R expressing B cells in leucocytes, respectively. (**G**) shows representative flow cytometric figures of MFI of IL‐18^+^ (i), IL‐18BP^+^ (ii) and IL‐18R^+^ (iii) B cells. (**H**--**J**) shows mean fluorescent intensity (MFI) of IL‐18, IL‐18BP and IL‐18R expression in B cells, respectively. Data are displayed as a boxplot for asthma patients (*n* = 31), and HC volunteers (*n* = 14), which indicates the median, interquartile range, the largest and smallest values for the number of volunteers indicated. *P* \< 0.05 was taken as statistically significant. ^\*^ *P* \< 0.05 compared with medium control in asthma group. ^‡^ *P* \< 0.05 compared with medium control in HC group. FMO = fluorescence minus one.](JCMM-22-354-g004){#jcmm13323-fig-0004}

Enhanced IL‐18R^+^ monocytes, but reduced IL‐18BP^+^ monocytes in OVA‐sensitized mouse blood {#jcmm13323-sec-0015}
--------------------------------------------------------------------------------------------

To understand further the influence of IL‐18 on monocytes, we investigated expression of IL‐18BP and IL‐18R in mouse monocytes with or without IL‐18 challenge. The results showed that the numbers of monocytes (Fig. [5](#jcmm13323-fig-0005){ref-type="fig"}A and B) and IL‐18R^+^ monocytes (Fig. [5](#jcmm13323-fig-0005){ref-type="fig"}A and D) were increased in OVA‐sensitized mouse blood. Sensitization reduced number of IL‐18BP^+^ monocytes (Fig. [5](#jcmm13323-fig-0005){ref-type="fig"}A and C). IL‐18 at 10 ng/ml enhanced number of monocytes by 87.2% and 14.4%, respectively (Fig. [5](#jcmm13323-fig-0005){ref-type="fig"}A and B), but eliminated IL‐18R^+^ monocytes (Fig. [5](#jcmm13323-fig-0005){ref-type="fig"}A and D) in blood of non‐sensitized and sensitized mice. OVA sensitization reduced MFI of IL‐18BP (Fig. [5](#jcmm13323-fig-0005){ref-type="fig"}Ei and F) and IL‐18R (Fig. [5](#jcmm13323-fig-0005){ref-type="fig"}Eii and G) on monocyte.

![Expressions of IL‐18BP and IL‐18 receptor (R) in monocytes of sensitized or non‐sensitized mouse blood in the presence or absence of IL‐18. (**A**) represents a gating strategy of CD11b^+^ Ly‐6G/Ly‐6C ^low^ monocyte expression in mouse leucocytes, and gating strategies for IL‐18BP and IL‐18R expression in monocytes of mouse blood. (**B--D**) demonstrates changes in percentages of monocytes, and proportions of IL‐18BP and IL‐18R expressing monocytes out of leucocytes, respectively, in response to IL‐18 (10 ng/ml) or normal saline (NS). (**E**) shows representative flow cytometric figures of MFI of IL‐18BP^+^ (i) and IL‐18R^+^ (ii) monocyte. (**F** and **G**) shows changes in mean fluorescent intensity (MFI) of IL‐18BP and IL‐18R expression in monocyte, respectively, in response to IL‐18 or NS. Data are displayed as a boxplot for sensitized (AM, *n* = 7) and non‐sensitized (HM, *n* = 6--7) mice, which indicates the median, interquartile range, the largest and smallest values for the number of volunteers indicated. *P* \< 0.05 was taken as statistically significant. ^\*^ *P* \< 0.05 increased expression compared with corresponding NS group, ^‡^ *P* \< 0.05 in comparison with HM NS group, ^†^ *P* \< 0.05 decreased expression compared with corresponding NS group. FMO = fluorescence minus one.](JCMM-22-354-g005){#jcmm13323-fig-0005}

Decreased IL‐18BP^+^ neutrophils, but increased IL‐18R^+^ neutrophils in OVA‐sensitized mouse blood {#jcmm13323-sec-0016}
---------------------------------------------------------------------------------------------------

We also investigated expression of IL‐18BP and IL‐18R in neutrophils of sensitized and non‐sensitized mice. The results showed that sensitization enhanced number of neutrophils in mouse blood (Fig. [6](#jcmm13323-fig-0006){ref-type="fig"}A and B). Compared with non‐sensitized mice, sensitized mice had decreased proportion of IL‐18BP^+^ neutrophils (Fig. [6](#jcmm13323-fig-0006){ref-type="fig"}A and C), but increased IL‐18R^+^ neutrophils (Fig. [6](#jcmm13323-fig-0006){ref-type="fig"}A and D) in their blood. Sensitization also enhanced MFI of IL‐18R on neutrophils (Fig. [6](#jcmm13323-fig-0006){ref-type="fig"}Eii and G). IL‐18 diminished MFI of IL‐18BP in neutrophils by 1.7% and 4.6% in non‐sensitized and sensitized mouse blood, respectively (Fig. [6](#jcmm13323-fig-0006){ref-type="fig"}Ei and F), and eliminated MFI of IL‐18R by 29.4% in sensitized mouse neutrophils (Fig. [6](#jcmm13323-fig-0006){ref-type="fig"}Eii and G).

![Expressions of IL‐18BP and IL‐18 receptor (R) in neutrophils of sensitized or non‐sensitized mouse blood in the presence or absence of IL‐18. (**A**) represents a gating strategy of CD11b^+^ Ly‐6G/Ly‐6C ^high^ neutrophil expression in mouse leucocytes, and gating strategies for IL‐18BP and IL‐18R expression in neutrophils of mouse blood. (**B**--**D**) demonstrates changes in percentages of neutrophils, and proportions of IL‐18BP and IL‐18R expressing neutrophils out of leucocytes, respectively, in response to IL‐18 (10 ng/ml) or normal saline (NS). (**E**) shows representative flow cytometric figures of MFI of IL‐18BP^+^ (i) and IL‐18R^+^ (ii) neutrophil. (**F** and **G**) shows changes in mean fluorescent intensity (MFI) of IL‐18BP and IL‐18R expression in neutrophil, respectively, in response to IL‐18 or NS. Data are displayed as a boxplot for sensitized (AM, *n* = 7) and non‐sensitized (HM, *n* = 6--7) mice, which indicates the median, interquartile range, the largest and smallest values for the number of volunteers indicated. *P* \< 0.05 was taken as statistically significant. ^‡^ *P* \< 0.05 compared NS in HM group, ^†^ *P* \< 0.05 compared with corresponding NS group. FMO = fluorescence minus one.](JCMM-22-354-g006){#jcmm13323-fig-0006}

Enhanced IL‐18BP^+^ macrophages, but reduced IL‐18R^+^ macrophages in OVA‐sensitized mouse lung {#jcmm13323-sec-0017}
-----------------------------------------------------------------------------------------------

As the influence of IL‐18 on expression of IL‐18BP and IL‐18R in macrophages remains unknown, we examined the issue in this study. The results showed that proportions of macrophages in dispersed lung cells were elevated in OVA‐sensitized mice (Fig. [7](#jcmm13323-fig-0007){ref-type="fig"}A and B). Sensitization also enlarged number of IL‐18BP^+^ macrophages (Fig. [7](#jcmm13323-fig-0007){ref-type="fig"}A and C), but reduced number of IL‐18R^+^ macrophages (Fig. [7](#jcmm13323-fig-0007){ref-type="fig"}A and D). IL‐18 at 10 ng/ml enhanced number of macrophages by 38.9% in non‐sensitized mice, but reduced percentage of macrophages by 41.8% in sensitized mice (Fig. [7](#jcmm13323-fig-0007){ref-type="fig"}A and B). IL‐18 up‐regulated expression of IL‐18BP (Fig. [7](#jcmm13323-fig-0007){ref-type="fig"}A and C) and IL‐18R (Fig. [7](#jcmm13323-fig-0007){ref-type="fig"}A and D) on lung macrophages by 64.4% and 144% in sensitized mice, respectively, but eliminated IL‐18R^+^ macrophages by 51.1% in non‐sensitized mice (Fig. [7](#jcmm13323-fig-0007){ref-type="fig"}A and D). IL‐18 had little effect on MFI of IL‐18BP (Fig. [7](#jcmm13323-fig-0007){ref-type="fig"}Ei and F) and IL‐18R (Fig. [7](#jcmm13323-fig-0007){ref-type="fig"}Eii and G) in mouse macrophage.

![Expressions of IL‐18BP and IL‐18 receptor (R) in macrophags of sensitized or non‐sensitized mouse lung cells in the presence or absence of IL‐18. (**A**) represents a gating strategy of F4/80^+^ CD11c^+^ macrophage expression in dispersed lung cells of mice, and gating strategies for IL‐18BP and IL‐18R expression in macrophages of mouse lung cells. (**B**--**D**) demonstrates changes in percentages of macrophages, and proportions of IL‐18BP and IL‐18R expressing macrophages out of dispersed lung cells, respectively, in response to IL‐18 (10 ng/ml) or normal saline (NS). (**E**) shows representative flow cytometric figures of MFI of IL‐18BP^+^ (i) and IL‐18R^+^ (ii) macrophage. (**F** and **G**) show changes in mean fluorescent intensity (MFI) of IL‐18BP and IL‐18R expression in macrophage, respectively, in response to IL‐18 or NS. Data are displayed as a boxplot for sensitized (AM, *n* = 7) and non‐sensitized (HM, *n* = 6--7) mice, which indicates the median, interquartile range, the largest and smallest values for the number of volunteers indicated. *P* \< 0.05 was taken as statistically significant. ^\*^ *P* \< 0.05 increased expression compared with corresponding NS group, ^‡^ *P* \< 0.05 in comparison with HM NS group, ^†^ *P* \< 0.05 decreased expression compared with corresponding NS group. FMO = fluorescence minus one.](JCMM-22-354-g007){#jcmm13323-fig-0007}
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IL‐18 belongs to the IL‐1 family, which plays a major role in innate as well as acquired immunity. As IL‐18 stimulates T cells to produce increased IFN‐γ, IL‐13 and IL‐5 [23](#jcmm13323-bib-0023){ref-type="ref"}, and IL‐13 and IL‐5 are potent Th2 cytokines, which play key pro‐inflammatory role in atopic asthma, it is believed that IL‐18 ought to be a causative factor for asthma. However, a study demonstrated that activation of the TLR2/NLRP3/IL‐18 axis can protect against asthma [3](#jcmm13323-bib-0003){ref-type="ref"}, complicating the role of IL‐18 in asthma. As IL‐18 carries out its biological functions mainly through its receptor IL‐18R [24](#jcmm13323-bib-0024){ref-type="ref"}, and IL‐18BP is a potent endogenous neutralizing antagonist of IL‐18, it is very likely that the role of IL‐18 in atopic asthma is decided by the balance between IL‐18, IL‐18BP and IL‐18R. We therefore examined expression of IL‐18, IL‐18BP and IL‐18R in parallel in inflammatory cells of asthma. Because monocytes/macrophages, neutrophils and B cells are involved in the pathogenesis of asthma, and they have close relationship with IL‐18, we first examined expression of IL‐18, IL‐18BP and IL‐18R in these cells.

We found for the first time that only 7.3% monocytes, 4.0% neutrophils and 16.8% B cells expressed IL‐18, and monocytes, neutrophils and B cells consist of approximately 2.3%, 70.6% and 1.8% leucocytes, which give 0.15%, 2.83% and 0.27% blood leucocytes are IL‐18^+^ monocytes, IL‐18^+^ neutrophils and IL‐18^+^ B cells, respectively, in asthmatic blood. Obviously, among the three cell types examined, neutrophils are predominant IL‐18 expressing leucocytes in asthmatic blood. In terms of density of IL‐18 expressed in these cells, MFIs of IL‐18 in monocytes, neutrophils and B cells of asthmatic blood are 712, 648 and 149, respectively, confirming that neutrophils are predominant IL‐18 expressing leucocytes in asthmatic blood.

We demonstrated for the first time that as much as 95% CD14^+^ monocytes, more than 70% neutrophils, and approximately 69.3% B cells in asthmatic or HC blood expressed IL‐18BP. This is an unexpected and striking finding as IL‐18BP is an endogenous antagonist with high neutralizing capacity in inhibition of action of IL‐18 [9](#jcmm13323-bib-0009){ref-type="ref"}. A 13‐fold (95%/7.3%) more monocytes, 17.5‐fold (70%/4%) more neutrophils and 4.1‐fold (69.3%/17%) more B cells express IL‐18BP than IL‐18 indicate that there is excessive amount of IL‐18BP to completely abolish actions of IL‐18 in asthma. Indeed, the ratios between plasma concentrations of IL‐18BP and IL‐18 were 1 in HC volunteers and 12.8 in patients with asthma, supporting further the fact that there is excessive amount of IL‐18BP to completely abolish actions of IL‐18 in both HC volunteers and asthmatic patients. We therefore believe that actions of IL‐18 in asthma depend on the balance between IL‐18 and IL‐18BP. A report that a severe IL‐18/IL‐18BP imbalance results in Th1 lymphocyte and macrophage activation in patients with secondary haemophagocytic syndrome [25](#jcmm13323-bib-0025){ref-type="ref"} may support the view that an IL‐18/IL‐18BP imbalance decides the role of IL‐18 in the pathogenesis of asthma.

The elevated plasma level of IL‐18BP in asthma patients indicates that excessive IL‐18BP is produced in the body. However, the expression of IL‐18BP by stimulated neutrophils, monocytes and B cells seems not to increase in asthmatic patients in comparison with healthy controls, which implicates that the excessive amount of plasma IL‐18BP is likely produced by certain cell types other than neutrophils, monocytes and B cells in the body.

We also discovered for the first time that approximately 64% IL‐18R^+^ monocytes, 1.7% IL‐18R^+^ neutrophils and 3.1% IL‐18R^+^ B cells are located in asthmatic blood. As for IL‐18BP, there should be 1.28% (64% × 2%) monocyte‐derived, 1.19% (1.7% × 70%) neutrophil‐derived and 0.045% (2.8% × 1.6%) B‐cell‐derived IL‐18R^+^ leucocytes in asthma blood. As a wide range of other cell types also expresses IL‐18R [8](#jcmm13323-bib-0008){ref-type="ref"}, it is very likely that huge number of IL‐18R expressing inflammatory cells is ready to react to IL‐18 in patients with asthma, suggesting the importance of IL‐18R in asthma.

We observed that ASWE and PPAE enhance IL‐18 expression in asthmatic monocytes; ASWE and DAE increase proportions of IL‐18BP and IL‐18 expression, and PPAE enhances IL‐18R expression in asthmatic neutrophils; DAE elevated MFI of IL‐18 and IL‐18BP in B cells of asthmatic blood. These results are a little confusing, but it implicates that allergens can enhance IL‐18, IL‐18BP and IL‐18R expression in its favourite cells in asthmatic blood.

In mouse model, OVA sensitization markedly reduced IL‐18BP^+^ monocytes and neutrophils, but enlarged number of IL‐18R^+^ monocytes and neutrophils in their blood, which implicates that sensitized mice should be more sensitive and responsive to IL‐18 stimulation than their human counterparts as a result of decreased IL‐18BP production and an enhanced IL‐18R expression. The finding that IL‐18 eliminated MFI of IL‐18R in mouse blood neutrophils and IL‐18R^+^ monocytes in mouse blood suggests that IL‐18 can down‐regulate expression of its own receptor, which may represent a self‐elimination mechanism of IL‐18, supporting the view that an IL‐18/IL‐18R imbalance decides the role of IL‐18 in the pathogenesis of asthma. The results that more than 78% human neutrophils in asthmatic blood, but \<1.9% neutrophils in sensitized mouse blood expressed IL‐18BP; and that 1.7% human neutrophils in asthmatic blood, but more than 90% neutrophils in sensitized mouse blood expressed IL‐18R, which show clear difference between human and mouse asthmatic models. It is rather difficult to explain these discrepancies, but they may hint the controversial functions of murine and human leucocytes in allergic inflammation [26](#jcmm13323-bib-0026){ref-type="ref"} and suggest once again the limitation of animal model in studying human diseases.

Induction of increased peripheral blood monocytes and lung macrophages by IL‐18 suggests that IL‐18 might promote monocytes to migrate and aggregate to local site and differentiate IL‐18BP^+^ macrophages during inflammatory process in mice. Although lack of direct evidence to prove IL‐18 can induce monocyte migration, the findings that IL‐18 administration can promote *in vivo* neutrophil [27](#jcmm13323-bib-0027){ref-type="ref"}, and mast cell accumulation [28](#jcmm13323-bib-0028){ref-type="ref"} in mice may support our above anticipation.

It was found that proportion of macrophages in dispersed lung cells was elevated in OVA‐sensitized mice. However, IL‐18 appeared to reduce number of macrophages in lung of sensitized mice. The observations that sensitization increased number of IL‐18BP^+^ macrophages, and that IL‐18 up‐regulated expression of IL‐18BP in lung macrophages of sensitized mice indicate that certain allergen may eliminate contribution of IL‐18 to asthma *via* IL‐18BP^+^ macrophages. Moreover, the finding that sensitization reduced number of IL‐18R^+^ macrophages in lung further decreases the capability for IL‐18 contributing to development of asthma. As macrophages are the major source of IL‐18BP within the submucosa [29](#jcmm13323-bib-0029){ref-type="ref"}, it is not difficult to understand IL‐18 is unlikely to contribute to the pathogenesis of asthma through lung macrophages.

In conclusion, we found for the first time that enhanced expression of IL‐18R in monocytes, neutrophils and B cells in atopic asthma and that majority of these cell types express IL‐18BP. As IL‐18 can modulate IL‐18BP and IL‐18R expression, the role of IL‐18 in atopic asthma is very likely to be decided by the balance of IL‐18/IL‐18BP/IL‐18R expression in response to different allergens (Fig. [8](#jcmm13323-fig-0008){ref-type="fig"}). Therefore, IL‐18R blocking or IL‐18BP activity enhancing therapies may be useful for treatment of asthma.

![Summary graph of the role of IL‐18 in atopic asthma: the interactive balance between IL‐18, IL‐18 binding protein (BP) and IL‐18 receptor (R) decides the action of IL‐18 in asthma.](JCMM-22-354-g008){#jcmm13323-fig-0008}
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